|Bid||40.00 x 1000|
|Ask||93.37 x 900|
|Day's Range||57.93 - 59.66|
|52 Week Range||37.61 - 93.39|
|Beta (5Y Monthly)||1.59|
|PE Ratio (TTM)||1.97|
|Earnings Date||Feb 06, 2023 - Feb 10, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Dec 02, 2021|
|1y Target Est||70.40|
Subscribe to Yahoo Finance Plus to view Fair Value for AZTA
Azenta, Inc. (Nasdaq: AZTA) today announced that it has acquired Ziath, Ltd. and its subsidiaries ("Ziath"). Based in Cambridge, UK, Ziath is a leading provider of 2D barcode readers for life sciences applications. Founded in 2005, Ziath's innovative 2D barcode readers are a key component of the laboratory automation workflow serving pharmaceutical, biotech and academic customers worldwide.
SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023. Dr. Nova succeeds Brian Birk, who has served as Chair of the Board of Directors at Exagen since 2018, and who will remain a member of the Board. Dr. Nova currently serves as President of Veracyte's (Nasdaq: VCYT) U.S. CLIA business where
Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 11, 2023, which includes a presentation beginning at 3:45 pm PST. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event.